Skip to main content

Table 2 Level and duration of maximum improvement for each endpoint describing the effects of the cimicoxib (2 mg/kg) administered by the oral route in the 4 Poor Metabolizers (PM) and 8 Extensive Metabolizers (EM) dogs

From: Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog

Endpoint

Maximum effect

Duration of the maximal effect

Total duration of the effect

 

PM

EM

PM

EM

PM

EM

Body temperature

87 ± 9%

84 ± 8%

19.6 h (from 2.1 to 21.7)

7 h (from 2.1 to 9.1 h)

25 h

13 h

Paw circumference

15 ± 3%

14 ± 2%

7 h (from 4.2 to 11.2 h)

9 h (from 2.2 to 11.2 h)

20 h

15 h

Skin plantar temperature

No plateau observed

38 ± 6%

Could not be determined

7 h (from 2.3 to 9.3 h)

22 h

13 h

Creeping speed

77 ± 7%

76 ± 9%

11.1 h (from 4.2 to 15.3 h)

7 h (from 2.2 to 9.2 h)

25 h

15 h

Clinical lameness score

1 or 2

1 or 2

10.9 h (from 4.8 to 15.7 h)

8.8 h (from 2.8 to 16 h)

not assessed

not assessed

Vertical normalized force

67 ± 6%

68 ± 7%

11.1 h (from 4.5 to 15.5 h)

6.9 h (from 2.6 to 9.5 h)

28 h

16 h

Analgesia

162 ± 53%

232 ± 45%

8.8 h (from 2.9 to 11.8 h)

7 h (from 2.9 to 9.8 h)

23 h

not assessed

  1. For the body temperature, the paw circumference, the creeping speed, the vertical normalised force obtained with a force plate and the analgesic effect, the maximal estimated effect was expressed as a percentage of control value, a 100% maximum effect indicating a return to control value (no kaolin challenge). Analgesia was assessed by the paw withdrawal time to a heat stimulus and values higher than 100% indicate that there was an analgesic effect of cimicoxib independent of its anti-inflammatory effect i.e. that the paw withdrawal time was longer after the cimicoxib administration than in control condition (no inflammation). For the lameness, the clinical score ranged from 0 (no lameness) to 5 (maximal lameness): a score of 1 corresponding to a slight lameness and a score of 2 to an obvious lameness. The duration of the effect (maximal or total) was directly obtained from raw data. Duration of total effect is the time when the effects of cimicoxib observed are superior to the placebo. Duration of maximal effect is duration during which a steady maximal effect was observed. Values are mean ± SD for the maximal effect and mean and range value for the duration of the maximum effect.